Hereditary Transthyretin Amyloidosis (HATTR) is caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently result in instability of TTR and subsequent fibril formation. HATTR can be sub-classified into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The deposition of TTR amyloid fibrils in various tissues leads to ATTR, including Familial ATTR (hereditary ATTR) and non-hereditary ATTR types. Familial ATTR is a rare disorder with unequal distribution all around the world.
This report contains market size and forecasts of Hereditary Transthyretin Amyloidosis (HATTR) in Global, including the following market information:
Global Hereditary Transthyretin Amyloidosis (HATTR) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hereditary Transthyretin Amyloidosis (HATTR) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hereditary Transthyretin Amyloidosis (HATTR) include Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Prothena, Lonis Pharmaceuticals, Eidos Therapeutics and Corino Therapeutics Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hereditary Transthyretin Amyloidosis (HATTR) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hereditary Transthyretin Amyloidosis (HATTR) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hereditary Transthyretin Amyloidosis (HATTR) Market Segment Percentages, by Type, 2021 (%)
Oral
Subcutaneous Injection
Others
Global Hereditary Transthyretin Amyloidosis (HATTR) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hereditary Transthyretin Amyloidosis (HATTR) Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Hereditary Transthyretin Amyloidosis (HATTR) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hereditary Transthyretin Amyloidosis (HATTR) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hereditary Transthyretin Amyloidosis (HATTR) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hereditary Transthyretin Amyloidosis (HATTR) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Alnylam Pharmaceuticals
Akcea Therapeutics
Prothena
Lonis Pharmaceuticals
Eidos Therapeutics
Corino Therapeutics Inc